Stockreport

BBOT Presents Preclinical Data Showing RAS:PI3Ka Breaker BBO-10203 Inhibits PI3Ka/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026

BridgeBio Oncology Therapeutics, Inc.  (BBOT) 
PDF BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Ka, leading to signaling inhibition without inhibiting the kinase activity of PI3Ka a [Read more]